Summary

Europe Veterinary Antibiotics Market Growth & Trends

The Europe veterinary antibiotics market size is estimated to reach USD 1.43 billion by 2030, registering a CAGR of 2.31% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising focus on animal-only antibiotics and ionophores, the launch of new products, and the increasing use of veterinary antibiotics are some of the major factors augmenting the industry's growth. In addition, the rising prevalence and incidence of livestock diseases and concerns regarding zoonoses are further propelling the industry's growth. The COVID-19 pandemic has affected the veterinary antibiotic business operations of key players and resulted in declined financial performance during the initial time.

The effect of the pandemic with various production and supply chain bottlenecks delayed the delivery of necessary raw materials or active ingredients and postponed certain research & development activities. However, with the easing of restrictions, manufacturers were able to supply antibiotics to meet the necessary veterinary requirements. Few major players have reported significant growth in antibiotic sales despite the pandemic. For instance, Virbac’s bovine antibiotic sales grew from USD 66.98 million in 2020 to USD 79.30 million in 2021. The global concern regarding antibiotic resistance is growing in agriculture and veterinary medicine. Despite the regulatory changes implemented by the European Medicines Agency (EMA) for restriction and ban on routine antibiotic use, the overall sales of veterinary antimicrobial active ingredients have observed significant growth in the past few years.

For instance, according to the EMA, overall veterinary antimicrobial active substance sales grew from 5,282 tonnes in 2019 to 5,562 tonnes in 2020. Furthermore, major players, such as Elanco, have shifted their focus to animal-only antibiotics, as a measure to address antibiotic resistance while also protecting animal health. Key players are implementing various strategic initiatives, such as mergers, partnerships, acquisitions, collaborations, and new product launches, to maintain their competitive edge. For instance, in December 2021, Virbac, in collaboration with Pharmgate, launched Tulissin, an antibiotic solution for swine and cattle with respiratory pathologies. These activities are expected to intensify the competition between major antibiotic manufacturers in the coming years.

Europe Veterinary Antibiotics Market Report Highlights

• The cattle animal type segment accounted for the largest revenue share in 2024 owing to the easy availability of cattle antibiotics and increased consumption of beef & dairy products

• By drug class, the penicillin segment held the largest revenue share in 2024. Penicillinis one of the most commonly sold antibiotic drug classes in Europe for veterinary application

• The oral solution segment led the market in 2024 owing to the easy & convenient usage of these dosage forms. These solutions are preferably dispensed in the drinking water

• Key factors contributing to the notable share of the U.K. include the easy availability of veterinary antibiotics and an increase in pet ownership & pet insurance rates

• The industry is fairly competitive owing to the presence of major players. Various strategic initiatives implemented by companies are greatly contributing to the growth of the industry.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Scope
1.1.2. Estimates And Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis
1.6.2. Global Market: CAGR Calculation
1.7. Research Scope and Assumptions
1.7.1. List of Secondary Sources
1.7.2. List of Primary Sources
1.7.3. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Europe Veterinary Antibiotics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Rising focus on animal-only antibiotics and ionophores
3.2.1.2. Growing Initiatives by key companies or launch of new products
3.2.1.3. Prudent and responsible use of antibiotics
3.2.2. Market Restraints Analysis
3.2.2.1. Stringent regulations
3.2.2.2. Decline in use of antibiotics
3.2.2.3. Active research on antibiotic alternatives
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenges Analysis
3.3. Europe Veterinary Antibiotics Market Analysis Tools
3.3.1. Porter’s Analysis
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental Landscape
3.3.2.5. Legal landscape
3.4. Covid-19 Analysis
3.5. Patent-Off Dates Analysis for Major Veterinary Antibiotics
3.6. Product Pipeline Analysis
3.7. Estimated Pet Population, by key countries
Chapter 4. Europe Veterinary Antibiotics Market: Animal Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Europe Veterinary Antibiotics Market Movement Analysis
4.3. Europe Veterinary Antibiotics Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
4.4. Pigs
4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
4.5. Cattles
4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
4.6. Sheep & Goats
4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
4.7. Poultry
4.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Europe Veterinary Antibiotics Market: Drug Class Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Europe Veterinary Antibiotics Market Movement Analysis
5.3. Europe Veterinary Antibiotics Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
5.4. Tetracyclines
5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.5. Penicillins
5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.6. Sulfonamides
5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.7. Macrolides
5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.8. Trimethoprim
5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.9. Lincosamides
5.9.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.10. Polymyxins
5.10.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.11. Aminoglycosides
5.11.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.12. Fluoroquinolones
5.12.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.13. Pleuromutilins
5.13.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
5.14. Other Drug Class
5.14.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Europe Veterinary Antibiotics Market: Dosage Form Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Europe Veterinary Antibiotics Market Movement Analysis
6.3. Europe Veterinary Antibiotics Market Size & Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
6.4. Oral Powders
6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.5. Oral Solutions
6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.6. Injections
6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Europe Veterinary Antibiotics Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3. Europe
7.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.2. Germany
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Insights
7.3.2.3. Germany Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Insights
7.3.3.3. UK Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Insights
7.3.4.3. France Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Insights
7.3.5.3. Italy Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Insights
7.3.6.3. Spain Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Netherlands
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Insights
7.3.7.3. Netherlands Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Insights
7.3.8.3. Denmark Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Belgium
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Insights
7.3.9.3. Belgium Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.10. Hungary
7.3.10.1. Key Country Dynamics
7.3.10.2. Competitive Insights
7.3.10.3. Hungary Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.11. Poland
7.3.11.1. Key Country Dynamics
7.3.11.2. Competitive Insights
7.3.11.3. Poland Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.12. Portugal
7.3.12.1. Key Country Dynamics
7.3.12.2. Competitive Insights
7.3.12.3. Portugal Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.13. Romania
7.3.13.1. Key Country Dynamics
7.3.13.2. Competitive Insights
7.3.13.3. Romania Veterinary Antibiotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Company Market Position Analysis/ Heat Map Analysis
8.3. Estimated Company Market Share Analysis, 2024
8.4. Strategy Mapping
8.4.1. Mergers & Acquisitions
8.4.2. Partnerships & Collaborations
8.4.3. Others
8.5. Company Profiles
8.5.1. Elanco
8.5.1.1. Participant’s Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Boehringer Ingelheim International GmbH.
8.5.2.1. Participant’s Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Zoetis
8.5.3.1. Participant’s Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Merck & Co., Inc.
8.5.4.1. Participant’s Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Ceva
8.5.5.1. Participant’s Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Vetoquinol S.A.
8.5.6.1. Participant’s Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Virbac
8.5.7.1. Participant’s Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Calier
8.5.8.1. Participant’s Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Bimeda, Inc.
8.5.9.1. Participant’s Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Prodivet pharmaceuticals sa/nv.
8.5.10.1. Participant’s Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
Chapter 9. Key Takeaways